A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies (NCT05131022)
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies
🩺 Plain-English Summary (8th-Grade Level)
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (62 Sites)
Showing the first 25 of 62 sites.
- City of Hope — Duarte, California
- University of California, San Francisco — San Francisco, California
- Colorado Blood Cancer Institute — Denver, Colorado
- Yale Cancer Center — New Haven, Connecticut
- University of Miami — Miami, Florida
- Florida Cancer Specialists — Sarasota, Florida
- Winship Cancer Institute of Emory University — Atlanta, Georgia
- Northwestern University — Chicago, Illinois
- National Institute of Health — Bethesda, Maryland
- Cayuga Medical Center — Ithaca, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Duke University Medical Center — Durham, North Carolina
- University of Cincinnati Medical Center — Cincinnati, Ohio
- Cleveland Clinic — Cleveland, Ohio
- University of Pennsylvania, Abramson Cancer Center — Philadelphia, Pennsylvania
- MD Anderson Cancer Center — Houston, Texas
- Huntsman Cancer Institute — Salt Lake City, Utah
- Medical College of Wisconsin — Milwaukee, Wisconsin
- CHU Angers — Angers,
- Hôpital Avicenne — Bobigny,
- CHU de Nantes — Nantes,
- CHU Bordeaux — Pessac,
- CHU de Poitiers — Poitiers,
- Institut Curie-Site Saint-Cloud — Saint-Cloud,
- CHRU de Nancy — Vandœuvre-lès-Nancy,
📞 Contact the Study Coordinator
Phone: (415) 417-3418
Email: clinicaltrials@nurixtx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Lymphocytic Leukemia (CLL)
- The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) — Stanford, California
- Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax — Basking Ridge, New Jersey
- A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies — New York, New York
- Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL — Stamford, Connecticut
- A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) — Houston, Texas
- Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib — Bethesda, Maryland
Explore by condition: All Chronic Lymphocytic Leukemia (CLL) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.